Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

Nur Nicholson Biography and Net Worth

Insider of Apellis Pharmaceuticals

Nur joined Apellis in August 2020 as our chief technical operations officer and brings over 25 years of global pharmaceutical experience in technical operations, clinical operations, and business operations and intelligence. Most recently, Nur was at Galderma where she was the head of global supply chain and also held the role of vice president, North America business operations and intelligence. Prior to Galderma, Nur was the head of global supply chain for the pharmaceutical franchise at Alcon, a Novartis division. During her more than 20-year career with Alcon, Nur held a number of roles in clinical and regulatory affairs operations, clinical infometrics and resource management, and sales operations. Nur holds a bachelor’s degree in chemistry from Middle East Technical University in Turkey and an Executive MBA from the M.J. Neely School of Business at Texas Christian University.

What is Nur Nicholson's net worth?: The estimated net worth of Nur Nicholson is at least $1.87 million as of March 13th, 2024. Ms. Nicholson owns 56,287 shares of Apellis Pharmaceuticals stock worth more than $1,869,291 as of December 21st. This net worth estimate does not reflect any other assets that Ms. Nicholson may own. Learn More about Nur Nicholson's net worth.
How do I contact Nur Nicholson?: The corporate mailing address for Ms. Nicholson and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Nur Nicholson's contact information.
Has Nur Nicholson been buying or selling shares of Apellis Pharmaceuticals?: Nur Nicholson has not been actively trading shares of Apellis Pharmaceuticals within the last three months. Most recently, Nur Nicholson sold 11,220 shares of the business's stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $57.56, for a transaction totalling $645,823.20. Following the completion of the sale, the insider now directly owns 56,287 shares of the company's stock, valued at $3,239,879.72. Learn More on Nur Nicholson's trading history.
Who are Apellis Pharmaceuticals' active insiders?: Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Apellis Pharmaceuticals?: During the last twelve months, insiders at the sold shares 30 times. They sold a total of 578,005 shares worth more than $32,477,597.17. The most recent insider tranaction occured on September, 16th when Director A. Sinclair Dunlop sold 37,000 shares worth more than $1,340,510.00. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.
Information on this page was last updated on 9/16/2024.

Nur Nicholson Insider Trading History at Apellis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/13/2024	Sell	11,220	$57.56	$645,823.20	56,287
1/29/2024	Sell	835	$64.14	$53,556.90	67,507
9/18/2023	Sell	20,350	$44.27	$900,894.50	53,284

Nur Nicholson Buying and Selling Activity at Apellis Pharmaceuticals

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Today's Range

Now: $33.21

$32.89

$34.27

50 Day Range

MA: $30.31

$26.18

$35.42

2 Week Range

Now: $33.21

$24.34

$73.80

Volume

3,733,222 shs

Average Volume

2,007,418 shs

Market Capitalization

$4.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

AI breakthrough about to upend industry

From Porter & Company | Ad

I urge you to watch it now.